Gilead's Harvoni beats Sovaldi, AbbVie's Viekira Pak in hep C drug safety: Advera

Drug safety numbers have been weighing in Gilead's ($GILD) favor lately, with recent analyses showing that its hep C superstars Harvoni and Sovaldi are safer than AbbVie's ($ABBV) rival med Viekira Pak. But Harvoni could be the safest option of the three, turning up the fewest reports of serious side effects, according to a new report by healthcare informatics firm Advera Health Analytics. More from FiercePharma

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.